Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007 (Third Quarter of Fiscal 2007)
Business Overview: Cardinal Health operates primarily through four reportable segments: Healthcare Supply Chain Services – Pharmaceutical, Healthcare Supply Chain Services – Medical, Clinical Technologies and Services, and Medical Products Manufacturing. The company recently realigned its reporting structure and committed to the sale of its Pharmaceutical Technologies and Services (PTS) business, which is now reported as discontinued operations.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Mar 31, 2007 |
Three Months Ended Mar 31, 2006 |
Nine Months Ended Mar 31, 2007 |
Nine Months Ended Mar 31, 2006 |
|---|---|---|---|---|
| Revenue | $21,867.1 | $20,213.2 | $64,589.1 | $58,412.5 |
| Gross Margin | $1,387.5 | $1,254.4 | $3,887.8 | $3,521.8 |
| Operating (Loss)/Earnings | $(9.8) | $534.9 | $953.1 | $1,357.5 |
| Net Earnings | $19.0 | $146.8 | $1,028.9 | $679.1 |
| Diluted EPS | $0.05 | $0.34 | $2.51 | $1.58 |
| Cash from Operating Activities | N/A | N/A | $1,409.8 | $1,624.1 |
| Cash and Equivalents (Ending) | $866.5 | $1,187.3 | $866.5 | $1,187.3 |
| Total Debt (Long-term + Current) | $3,195.9 | N/A | $3,195.9 | N/A |
Note: Debt figures calculated as Current portion of long-term obligations ($296.9M) plus Long-term obligations ($2,899.0M) as of March 31, 2007.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 8% ($1.7 billion) for the quarter and 11% ($6.2 billion) for the nine-month period compared to the prior year, driven by strong demand in pharmaceutical distribution and growth in clinical technologies.
- Operating Loss: The company reported an operating loss of $9.8 million for the quarter, a significant decline from $534.9 million in earnings the prior year. This was primarily due to a $600 million litigation reserve.
- Special Items: Total special items increased to $612.0 million for the quarter (from $13.3 million prior year) and $653.8 million for the nine months (from $47.8 million prior year). The increase is almost entirely attributable to a $600 million reserve for shareholder litigation.
- Discontinued Operations: Earnings from discontinued operations were $23.9 million for the quarter and $426.9 million for the nine months, largely due to a $425 million net tax benefit recognized upon the decision to sell the PTS Business.
- Share Repurchases: The company repurchased approximately $1.4 billion of common shares in the quarter and $2.1 billion for the nine-month period.
Guidance, Outlook, and Risks
- PTS Business Sale: The company completed the sale of the PTS Business on April 10, 2007, for approximately $3.2 billion in cash. Management plans to use the after-tax net proceeds (approx. $3.1 billion) to repurchase shares.
- Restructuring: A third phase of the global restructuring program was announced on April 30, 2007, involving the relocation of the Healthcare Supply Chain Services – Medical headquarters to Dublin, Ohio. The program is expected to be substantially completed by the end of fiscal 2009.
- Legal Contingencies:
- Shareholder Litigation: A $600 million reserve was recorded for federal securities actions. A proposed settlement was approved by the Board but remains subject to court and class representative approval.
- SEC Investigation: The company has reached an agreement-in-principle with the SEC regarding a potential settlement involving a $35 million penalty (reserved in prior periods).
- Alaris SE Pump Recall: A voluntary field corrective action was initiated. The company received FDA approval for its corrective action plan in March 2007 and reconditioning plan in April 2007.
- Liquidity: The company maintains a $1.5 billion commercial paper program and a $1.5 billion revolving credit facility. Management believes it has adequate capital resources to fund operations, debt service, and potential legal settlements.
Key Facts for Investor Verification
- Impact of Litigation Reserve: Verify the final status of the $600 million shareholder litigation settlement and whether the reserved amount is sufficient or if additional charges may be required.
- Discontinued Operations Tax Benefit: Confirm the realization of the $425 million net tax benefit associated with the PTS Business sale and its impact on future tax provisions.
- Share Repurchase Utilization: Monitor the deployment of the $3.1 billion in proceeds from the PTS sale for share repurchases under the $4.5 billion authorization.
- Segment Profitability: Review the profitability of the Healthcare Supply Chain Services – Pharmaceutical segment, which accounts for approximately 86% of total revenue, particularly regarding bulk vs. non-bulk customer margins.
- Regulatory Compliance: Track the resolution of the SEC investigation and the ongoing FTC and state attorney general inquiries regarding antitrust and Medicaid claims.